Zhang Hua-Yong, Zhang Yong
Department of Cardiology, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
Clinical Medical Research Center for Birth Defect Prevention and Treatment in Wuhan, China.
Medicine (Baltimore). 2024 Dec 27;103(52):e41056. doi: 10.1097/MD.0000000000041056.
Long QT interval syndrome type 7 (LQT7) is a rare hereditary multisystem disorder characterized by a classic triad of ventricular arrhythmias with QT interval prolongation, periodic paralysis, and distinctive skeletal and facial features. The Kir2.1 protein is encoded by the KCNJ2 gene, which has been associated with LQT7.
We report an 8-year-old boy who presented with frequent premature ventricular contraction with QRS electrical alternans, QT interval prolongation, bidirectional ventricular tachycardia, and learning disability with poor school performance. Gene sequencing revealed a novel missense mutation in the KCNJ2 gene (c.224 C>A, p.Thr75Lys).
The patient was diagnosed as LQT7 and a learning disability.
During the follow-up period, the ventricular arrhythmias were difficult to treat with β-blocker. Due to the frequent premature ventricular contraction and bidirectional ventricular tachycardia, radiofrequency catheter ablation was tried but failed.
An implantable cardioverter-defibrillator was recommended due to the recurrent syncope, but the boy's legal guardian rejected the recommendation, opting to continue his treatment in another hospital.
Clinical management is mostly focused on reducing adverse cardiac events. As a first option, β-blockers are often chosen as treatments for LQT7 patients, but there is no clear evidence for their effectiveness in preventing fatal arrhythmias. If the drug treatment is not effective, radiofrequency catheter ablation can be considered. However, it may be difficult to target accurately the right spot, and the attempt of the radiofrequency catheter ablation failed. Therefore, after ineffective medical treatment, implantable cardioverter-defibrillator implantation could be an option for patients with life-threatening cardiac events.
7型长QT间期综合征(LQT7)是一种罕见的遗传性多系统疾病,其特征为具有QT间期延长的室性心律失常、周期性麻痹以及独特的骨骼和面部特征组成的经典三联征。Kir2.1蛋白由KCNJ2基因编码,该基因与LQT7相关。
我们报告一名8岁男孩,他出现频发室性早搏伴QRS电交替、QT间期延长、双向室性心动过速以及学习障碍且学业成绩不佳。基因测序显示KCNJ2基因存在一个新的错义突变(c.224 C>A,p.Thr75Lys)。
该患者被诊断为LQT7和学习障碍。
在随访期间,β受体阻滞剂难以治疗室性心律失常。由于频发室性早搏和双向室性心动过速,尝试了射频导管消融但失败了。
由于反复晕厥,建议植入植入式心脏复律除颤器,但男孩的法定监护人拒绝了该建议,选择在另一家医院继续治疗。
临床管理主要集中在减少不良心脏事件。作为首选,β受体阻滞剂常被选作LQT7患者的治疗药物,但尚无明确证据表明其在预防致命性心律失常方面的有效性。如果药物治疗无效,可以考虑射频导管消融。然而,可能难以准确靶向正确部位,射频导管消融尝试失败。因此,在药物治疗无效后,对于有危及生命的心脏事件的患者,植入植入式心脏复律除颤器可能是一种选择。